Year: 2011

  • 2023 Result of Annual General Meeting – All Resolutions Passed

    ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, held its AGM earlier today. The Company is pleased to announce that all resolutions were duly passed, details of which are contained in the table below. Resolution For % For Against % Against Withheld 1. To receive the accounts of the Company for the year…

  • Proactive

    Proactive – ImmuPharma “delighted” to push on with new clinical trial 28 June 2023 ImmuPharma “absolutely delighted” to push on with new clinical trial.

  • Phase 2/3 adaptive clinical trial of P140 (Lupuzor™) in Lupus to commence following FDA meeting

    ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is pleased to announce that the Phase 2/3 adaptive clinical trial of P140 (Lupuzor™) in patients with systemic lupus erythematosus (“SLE/Lupus”) is to commence in H2 2023.  Key highlights: Following the receipt of comprehensive guidance from the Food and Drug Administration (“FDA”) in 3 separate…

  • Immupharma PLC Warrants Outstanding

    To view warrants outstanding click here

  • Notice of AGM & Annual Report & Accounts

    ImmuPharma PLC (LSE AIM: IMM), the specialist drug discovery and development company, confirms that the Notice of Annual General Meeting (“AGM”) has today been posted to shareholders. The Annual Report and Accounts for the year ended 31 December 2022 has also been posted to shareholders today. These documents will be available shortly, in electronic form,…

  • Proactive – Tim McCarthy

    Proactive – ImmuPharma “looking forward” with quiet confidence” to FDA response 24 May 2023 Tim McCarthy, CEO of ImmuPharma talks to Proactive Investors on the recent positive guidance from the FDA on its autoimmune program, CIDP – 24 May 2023

  • Positive guidance from the FDA Pre-IND meeting supports an IND application and a Phase 2/3 adaptive clinical trial of P140 in CIDP

    ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is pleased to announce further positive progress in its late-stage clinical program in patients with chronic idiopathic demyelinating polyneuropathy (“CIDP”), which is a further debilitating auto-immune condition within the Company’s P140 platform Key highlights: ImmuPharma has received positive support and guidance from the Food and…

  • TR1 Lanstead holding 10 May 2023

    TR-1: Standard form for notification of major holdings To view click here

  • FINAL RESULTS ANNOUNCEMENT for the year ended 31 December 2022

    ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, is pleased to announce its final results for the twelve months ended 31 December 2022 (the “Period”). Key Highlights (including post Period review)  Financial Loss for the Period of £3.8m (2021: £8.2m) Research and development expenses of £2.0m (2021: £3.7m) Administrative expenses of £0.8m…

  • Proactive Interview – Tim McCarthy

    Proactive – ImmuPharma “looking forward” to upcoming FDA meetings 27 April 2023 Tim McCarthy, CEO talks to Proactive on recent positive newsflow and his optimism on the forthcoming FDA meetings for Lupuzor for lupus and CIDP – 27 April 2023